Form 8-K Viridian Therapeutics, For: Sep 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Form 8-K Viridian Therapeutics, For: Sep 10
September 12, 2024 5:07 AM EDT
Goldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "We update our model to reflect increased POS for veligrotug (VRDN-001) following positive topline results from the Ph. 3 THRIVE... More
September 10, 2024 1:08 PM EDT
Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PoS for VRDN-001/003 to 80% from 66% following positive topline data from the Ph3 THRIVE study (Our Take... More
September 10, 2024 11:41 AM EDT
BTIG analyst Julian Harrison raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $56.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "15wk THRIVE (active TED Phase 3) data show veligrotug (fka VRDN-001) with at least comparable proptosis efficacy vs. Tepezza at 24wk, and veligrotug's placebo-corrected rates of diplopia resolution and hearing... More
